Cover Image

Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Michael H. Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J. Bahlis, Joaquin Martinez‐Lopez, Guenther Koehne, Paula Rodriguez‐Otero, H. Miles Prince, Andrea Viqueira, Eric Leip, Umberto Conte, Sharon T. Sullivan, Alexander M. Lesokhin
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	HemaSphere
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
by: Patrick Born, et al.
Published: (2025)

Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma
by: Nil Albiol, et al.
Published: (2026)

Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD‐1 blockade
by: Thomas M. Kuczmarski, et al.
Published: (2025)

High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
by: Andrea Manubens, et al.
Published: (2025)

Impact of second autologous stem‐cell transplantation at relapsed multiple myeloma: A French multicentric real‐life study
by: Axel André, et al.
Published: (2024)

Disease‐burden‐adapted immunotherapy protocol for primary refractory or high‐risk relapsed pediatric acute lymphoblastic leukemia
by: Sanaa Khan, et al.
Published: (2024)

Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma
by: Matthew Mei, et al.
Published: (2025)

Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
by: Arnon P. Kater, et al.
Published: (2024)

Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma
by: Sophia Stock, et al.
Published: (2025)

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis
by: Maeve A. O'Reilly, et al.
Published: (2024)

Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study
by: André Baruchel, et al.
Published: (2025)

Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM‐2 study
by: Stefano Luminari, et al.
Published: (2026)

Navigating the evolving management of smoldering multiple myeloma
by: M. Bakri Hammami, et al.
Published: (2026)

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
by: Gian Matteo Rigolin, et al.
Published: (2024)

The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
by: Andrew D. Zelenetz, et al.
Published: (2024)

Efficacy and safety of the academic anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma
by: Núria Martínez‐Cibrián, et al.
Published: (2025)

Real‐life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy‐cell leukemia: A multicenter Italian retrospective study (HCL‐PG03R)
by: Luca De Carolis, et al.
Published: (2025)

Cell‐free DNA for detection and monitoring of extramedullary AML relapse
by: Henri C. Hupe, et al.
Published: (2025)

Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry
by: Jean Galtier, et al.
Published: (2025)

Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study
by: Meral Beksac, et al.
Published: (2026)

High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience
by: Veronica González‐Calle, et al.
Published: (2024)

Central nervous system myeloma: Pathogenesis, diagnostic challenges, and practical management strategies
by: Eirini Katodritou, et al.
Published: (2025)

Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
by: Cristina De Ramón, et al.
Published: (2024)

Interferon gamma‐mediated prevention of tumor progression in a mouse model of multiple myeloma
by: Zoltán Kellermayer, et al.
Published: (2024)

Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
by: Kazimierz Groen, et al.
Published: (2024)

Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma
by: Larissa Haertle, et al.
Published: (2024)

Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma
by: Juan‐Jose Garces, et al.
Published: (2025)

CDK6 protein expression is associated with disease progression and treatment resistance in multiple myeloma
by: Johannes Steinhart, et al.
Published: (2024)

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
by: Ola Landgren, et al.
Published: (2025)

Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53‐deficient myeloma cells
by: Romane Durand, et al.
Published: (2024)

Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
by: Wassilis S. C. Bruins, et al.
Published: (2024)

Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma
by: Thomas C. Wiemers, et al.
Published: (2026)

The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma
by: Anna de Daniel, et al.
Published: (2024)

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant
by: Benjamin A. Derman, et al.
Published: (2025)

Correction to “Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network”
Published: (2025)

Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
by: Sonia Morè, et al.
Published: (2025)

Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
by: Niels W. C. J. van de Donk, et al.
Published: (2025)

Impact of the kinetics of circulating anti‐BCMA CAR‐T cells and normal lymphocytes on the outcome of MM patients
by: Sara Gutiérrez‐Herrero, et al.
Published: (2025)

Genetic evolution and relapse‐associated mutations in adult T‐cell acute lymphoblastic leukemia patients treated in PETHEMA trials
by: Celia González‐Gil, et al.
Published: (2025)

30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
by: Enrique M. Ocio, et al.
Published: (2024)